Chronic Lymphocytic Leukemia | Specialty

Guidelines for Chronic Lymphocytic Leukemia

January 19th 2021

Dr Brown and Dr Ghia discuss the European Society for Medical Oncology [ESMO] and International Workshop on Chronic Lymphocytic Leukemia [iwCLL] recommended guidelines in assessing and treating chronic lymphocytic leukemia.

Rapid Readouts: Efficacy of Novel Targeted Therapies Post-MURANO Study

January 18th 2021

CLL Paradigm Prepares to Expand With Novel Therapies as Chemo Is Phased Out

January 13th 2021

James Gerson, MD, discusses how he navigates treatment selection for patients with CLL and exciting developments in the pipeline.

Ibrutinib/Rituximab Approved in Canada for CLL

January 13th 2021

January 13, 2021 - Health Canada has approved the combination of ibrutinib and rituximab for use in patients with treatment-naïve chronic lymphocytic leukemia.

COVID-19 Pandemic Restructures Care in CLL

January 12th 2021

As the coronavirus disease 2019 pandemic continues to pose challenges, health care providers struggle with decisions on how to balance the risk of severe acute respiratory syndrome coronavirus 2 transmission with the need to treat patients’ underlying conditions.

Frontline CLL Treatment: Addressing Unmet Needs

January 8th 2021

Allogeneic Transplantation for CLL

January 8th 2021

Relapsed/Refractory CLL: Repeat Molecular Testing

January 8th 2021

Therapeutic Sequencing in Relapsed/Refractory CLL

January 8th 2021

CLL Patient Management During COVID-19 and Telehealth

January 8th 2021

CLL Treatment Approaches During COVID-19

January 8th 2021

Frontline CLL: Treatment Algorithms

January 8th 2021

Minimal Residual Disease in CLL

January 8th 2021

Frontline CLL Treatment With Fixed-Duration Regimens

January 8th 2021

Anti-BCL2/CD20 Combination Therapy for Frontline CLL

January 8th 2021

Anti-CD20/BTKi Therapy for Frontline CLL

January 8th 2021

BTK Monotherapy for Frontline CLL

January 8th 2021

Selecting Frontline Therapy to Treat CLL

January 8th 2021

Dr. Hobbs on Choosing Optimal Second-Line Treatment Option for TKI-Resistant CLL

January 7th 2021

Gabriela Hobbs, MD, shares advice on how to choose the appropriate second-line treatment option for patients with chronic lymphocytic leukemia who are resistant to TKIs.

Dr. Barr on Exploring U2 Plus Venetoclax in Relapsed/Refractory CLL

January 4th 2021

Paul M. Barr, MD, discusses exploring umbralisib plus ublituximab plus venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia.